GT Biopharma Inc
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surfa… Read more
GT Biopharma Inc (GTBP) - Total Liabilities
Latest total liabilities as of September 2025: $1.32 Million USD
Based on the latest financial reports, GT Biopharma Inc (GTBP) has total liabilities worth $1.32 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GT Biopharma Inc - Total Liabilities Trend (1983–2024)
This chart illustrates how GT Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
GT Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of GT Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Prismaflex Intl
PA:ALPRI
|
France | €24.84 Million |
|
King Tire Indonesia
JK:TYRE
|
Indonesia | Rp259.87 Billion |
|
Australian Oilseeds Holdings Limited Ordinary Shares
NASDAQ:COOT
|
USA | $29.72 Million |
|
Coastal Greenland Limited
F:CGR0
|
Germany | €558.66 Million |
|
Palamina Corp
OTCQB:PLMNF
|
USA | $1.64 Million |
|
Korea Plasma Technology U Co.Ltd
KQ:054410
|
Korea | ₩39.75 Billion |
|
Pop Culture Group Co Ltd
NASDAQ:CPOP
|
USA | $93.27 Million |
Liability Composition Analysis (1983–2024)
This chart breaks down GT Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GT Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GT Biopharma Inc (1983–2024)
The table below shows the annual total liabilities of GT Biopharma Inc from 1983 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $5.90 Million | -11.02% |
| 2023-12-31 | $6.63 Million | +32.61% |
| 2022-12-31 | $5.00 Million | -51.24% |
| 2021-12-31 | $10.26 Million | -70.77% |
| 2020-12-31 | $35.09 Million | +78.09% |
| 2019-12-31 | $19.71 Million | +40.47% |
| 2018-12-31 | $14.03 Million | +423.67% |
| 2017-12-31 | $2.68 Million | -85.86% |
| 2016-12-31 | $18.95 Million | -62.57% |
| 2015-12-31 | $50.62 Million | +66.18% |
| 2014-12-31 | $30.46 Million | +370.02% |
| 2013-12-31 | $6.48 Million | -1.23% |
| 2012-12-31 | $6.56 Million | +25.47% |
| 2011-12-31 | $5.23 Million | -7.50% |
| 2010-12-31 | $5.65 Million | -20.46% |
| 2009-12-31 | $7.11 Million | +66.46% |
| 2008-12-31 | $4.27 Million | +32.28% |
| 2007-12-31 | $3.23 Million | -58.63% |
| 2006-12-31 | $7.80 Million | +82.80% |
| 2005-12-31 | $4.27 Million | +59.25% |
| 2004-12-31 | $2.68 Million | +145.20% |
| 2003-12-31 | $1.09 Million | +42.50% |
| 2002-12-31 | $767.00K | -35.44% |
| 2001-12-31 | $1.19 Million | -23.45% |
| 2000-12-31 | $1.55 Million | -37.80% |
| 1999-12-31 | $2.50 Million | -37.63% |
| 1998-12-31 | $4.00 Million | -31.03% |
| 1997-12-31 | $5.80 Million | +65.71% |
| 1996-12-31 | $3.50 Million | -37.50% |
| 1995-12-31 | $5.60 Million | +24.44% |
| 1994-12-31 | $4.50 Million | +1400.00% |
| 1993-12-31 | $300.00K | -50.00% |
| 1992-12-31 | $600.00K | +200.00% |
| 1991-12-31 | $200.00K | 0.00% |
| 1990-12-31 | $200.00K | -60.00% |
| 1989-12-31 | $500.00K | +66.67% |
| 1988-12-31 | $300.00K | +50.00% |
| 1987-12-31 | $200.00K | -60.00% |
| 1986-12-31 | $500.00K | +400.00% |
| 1985-12-31 | $100.00K | -66.67% |
| 1984-12-31 | $300.00K | -25.00% |
| 1983-12-31 | $400.00K | -- |